Minshan Chen
About
Minshan Chen is a scholar working on Hepatology, Surgery and Epidemiology.
According to data from OpenAlex, Minshan Chen has authored 190 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 143 papers in Hepatology, 62 papers in Surgery and 57 papers in Epidemiology. Recurrent topics in Minshan Chen's work include Hepatocellular Carcinoma Treatment and Prognosis (139 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (58 papers) and Liver Disease Diagnosis and Treatment (39 papers). Minshan Chen is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (139 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (58 papers) and Liver Disease Diagnosis and Treatment (39 papers). Minshan Chen collaborates with scholars based in China, United States and Hong Kong. Minshan Chen's co-authors include Yaojun Zhang, Li Xu, Masatoshi Kudo, Rong Guo, Lucinda Orsini, Philip J. Johnson, Myron Schwartz, Pei‐Jer Chen, Lewis R. Roberts and Morris Sherman and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Minshan Chen
185 papers receiving 5.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Minshan Chen China | 35 | 3.1k | 1.4k | 1.3k | 1.0k | 949 | 190 | 5.1k | ||
| Jian‐Hong Zhong China | 33 | 2.5k 0.8× | 1.5k 1.1× | 987 0.7× | 943 0.9× | 1.0k 1.1× | 178 | 4.3k | ||
| Min-Shan Chen China | 32 | 3.3k 1.1× | 1.9k 1.4× | 1.4k 1.0× | 896 0.9× | 1.3k 1.4× | 58 | 5.3k | ||
| Baogang Peng China | 32 | 1.7k 0.6× | 880 0.6× | 1.2k 0.9× | 875 0.8× | 810 0.9× | 103 | 3.6k | ||
| Boheng Zhang China | 33 | 2.2k 0.7× | 1.6k 1.1× | 1.1k 0.8× | 1.0k 1.0× | 785 0.8× | 83 | 4.1k | ||
| Jinsil Seong South Korea | 39 | 2.9k 0.9× | 1.1k 0.8× | 1.8k 1.4× | 726 0.7× | 1.7k 1.8× | 249 | 5.4k | ||
| Osamu Nakashima Japan | 46 | 4.6k 1.5× | 2.9k 2.1× | 1.7k 1.3× | 1.2k 1.2× | 2.2k 2.3× | 204 | 7.5k | ||
| Shinichi Aishima Japan | 40 | 1.8k 0.6× | 1.5k 1.1× | 2.2k 1.6× | 1.1k 1.0× | 2.1k 2.2× | 167 | 5.1k | ||
| Kenichi Wakasa Japan | 40 | 2.2k 0.7× | 2.1k 1.5× | 1.5k 1.1× | 808 0.8× | 1.5k 1.6× | 260 | 6.5k | ||
| Kazuomi Ueshima Japan | 34 | 3.4k 1.1× | 2.0k 1.4× | 649 0.5× | 615 0.6× | 765 0.8× | 156 | 4.4k | ||
| Shigeru Marubashi Japan | 42 | 2.0k 0.7× | 1.1k 0.8× | 2.1k 1.6× | 1.4k 1.4× | 2.6k 2.7× | 269 | 6.0k |
Countries citing papers authored by Minshan Chen
Since
Specialization
Citations
This map shows the geographic impact of Minshan Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minshan Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minshan Chen more than expected).
Fields of papers citing papers by Minshan Chen
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Minshan Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minshan Chen. The network helps show where Minshan Chen may publish in the future.
Co-authorship network of co-authors of Minshan Chen
This figure shows the co-authorship network connecting the top 25 collaborators of Minshan Chen. A scholar is included among the top collaborators of Minshan Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Minshan Chen. Minshan Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Hu, Zili, Min Deng, Yizhen Fu, et al.. (2025). Neoadjuvant hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin for resectable single large hepatocellular carcinoma. International Journal of Surgery. 111(6). 3850–3858.
2.
Li, Xu, Jinzhang Chen, Chang Liu, et al.. (2024). Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial. BMC Medicine. 22(1). 172–172.
3.
Wang, Qianyu, Hu Li, Juncheng Wang, et al.. (2024). Transarterial therapy combined with bevacizumab plus immune checkpoint inhibitors as a neoadjuvant therapy for locally advanced HCC. Frontiers in Immunology. 15. 1469302–1469302.
4.
Wang, Xin, Yizhen Fu, Weijie Wu, et al.. (2024). YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment. Molecular Cancer. 23(1). 186–186.
5.
Wu, Weijie, Hao Zou, Zhongguo Zhou, et al.. (2024). The CRAFITY score emerges as a paramount prognostic indicator in hepatocellular carcinoma patients received Lenvatinib and Pembrolizumab. Frontiers in Immunology. 15. 1474456–1474456.
6.
Zhu, Xiaodong, Hui‐Chuan Sun, Feng Shen, et al.. (2024). The safety of atezolizumab plus bevacizumab (atezo/bev) treatment in Chinese patients (pts) with hepatocellular carcinoma (HCC) with active hepatitis B virus (HBV) infection: Results from the TALENTop study.. Journal of Clinical Oncology. 42(16_suppl). e16168–e16168.
7.
Wu, Weijie, et al.. (2023). Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. Volume 10. 1849–1859.
8.
Wang, Jiongliang, Juncheng Wang, Yangxun Pan, et al.. (2023). Systemic Inflammation Score Using Pretherapeutic Inflammatory Markers to Predict Prognosis for Hepatocellular Carcinoma Patients After Hepatic Arterial Infusion Chemotherapy. Journal of Hepatocellular Carcinoma. Volume 10. 2133–2145.
9.
Hu, Zili, Weijie Wu, Zhongguo Zhou, et al.. (2023). Efficacy of additional locoregional therapy based on systemic therapy after intrahepatic progression for BCLC stage B/C hepatocellular carcinoma: A real-world study. International Immunopharmacology. 127. 111413–111413.
10.
Hu, Zili, Yizhen Fu, Dandan Hu, et al.. (2023). Laparoscopic Hepatectomy versus Open Hepatectomy After Conversion Therapy Using Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy for Patients with Initially Unresectable Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. Volume 10. 1157–1167.
11.
Yuan, Yichuan, Wei He, Jiliang Qiu, et al.. (2023). TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. International Journal of Surgery. 109(5). 1222–1230.
12.
Liu, Changjun, et al.. (2023). Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis. Clinical and Translational Medicine. 13(3). e1214–e1214.
13.
Hu, Zili, Yu Yuan, Qingbo Liu, et al.. (2022). Development and Validation of Prognostic Nomograms for Hepatocellular Carcinoma After Hepatectomy Based on Inflammatory Markers. Journal of Hepatocellular Carcinoma. Volume 9. 1403–1413.
14.
Hu, Zili, Juncheng Wang, Li Xu, et al.. (2022). Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation. Viruses. 14(4). 656–656.
15.
Zhou, Zhongguo, Jinbin Chen, Rongxin Zhang, et al.. (2020). Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients. Cancer Communications. 40(8). 355–369.
16.
Pan, Yangxun, Jinbin Chen, Dandan Hu, et al.. (2020). Single versus multiple port laparoscopic left lateral sectionectomy for hepatocellular carcinoma: A retrospective comparative study. International Journal of Surgery. 77. 15–21.
17.
Wu, Chong, Jie Lin, Yulan Weng, et al.. (2020). Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma. Journal of Clinical Investigation. 130(9). 4679–4693.
18.
Wu, Chong, Mingyu Liu, Jie Lin, et al.. (2018). Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis. Journal of Clinical Investigation. 128(8). 3425–3438.
19.
Chen, Jinbin, Jia Huang, Minshan Chen, et al.. (2017). Transcatheter arterial chemoembolization (TACE) versus hepatectomy in hepatocellular carcinoma with macrovascular invasion: a meta-analysis of 1683 patients. Journal of Cancer. 8(15). 2984–2991.
20.
Chen, Minshan. (2008). Percutaneous radiofrequency ablation and surgical resection for small hepatocellular carcinoma:a comparative study.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jian‐Hong Zhong Breakdown of academic impact, for papers by Min-Shan Chen Breakdown of academic impact, for papers by Baogang Peng Breakdown of academic impact, for papers by Boheng Zhang Breakdown of academic impact, for papers by Jinsil Seong Breakdown of academic impact, for papers by Osamu Nakashima Breakdown of academic impact, for papers by Shinichi Aishima Breakdown of academic impact, for papers by Kenichi Wakasa Breakdown of academic impact, for papers by Kazuomi Ueshima Breakdown of academic impact, for papers by Shigeru Marubashi